Our research and development efforts are focused on the identification and qualification of new pipeline opportunities. We apply our proprietary HGMS technology platform to these areas of unmet clinical need to develop ancillary diagnostic and prognostic tests.
Our technology platform is well suited to address clinically challenging problems for which collaborative research partners can provide us with one of the following types of specimens:
We are focused on collaborative research and development projects with the potential to result in ancillary diagnostic and prognostic tests that improve a physician's ability to:
A new project is typically initiated with a discussion about our technology and how it might address an unmet clinical need. While this initial discussion can generally be accomplished via teleconference or webinar, we are willing to arrange a time for a New River Labs representative to visit your institution, present our capabilities, and answer any questions that you or your team may have.
The first step is to conduct a pilot study to determine if molecular differences can be detected between phenotypes. Typically, about 25 specimens per phenotype are used in this phase of the project, allowing us to achieve statistical confidence in the results.
If the results from the pilot study look promising, the project is then expanded to provide a sufficient number of specimens to generate a classification algorithm (training set) and to evaluate its accuracy in an independent set of specimens (validation set). The number of specimens necessary for this phase will depend on the complexity of the test being developed, but generally, this phase requires a couple hundred specimens.
Finally, an additional, smaller set of specimens will be needed to perform method validation to meet the requirements under CLIA related to the performance of high complexity clinical laboratory testing. Upon successful completion of this phase, we will be able to offer our test to relevant physicians.
In addition, they help us increase awareness of the test, by means of scientific presentations and publications, within the relevant physician community.
Please email firstname.lastname@example.org if you have an idea that you would like to discuss with a member of our research and development team.